BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
ALS (amyotrophic lateral sclerosis) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for amyotrophic lateral sclerosis: 82 (64 sponsors; 10 newly posted in the last 180 days, 5 stopped in the last 180 days; 6 new-entrant sponsors). Momentum score 12.2, rank 56 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 21, Phase 2 22, Phase 3 12, Phase 4 1, N/A 24.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AB Science | 2 | P3 2 | 0 | 0 |
| Biogen BIIB | 4 | NA 1, P3 1, P2 1, P4 1 | 1 | 0 |
| Brainstorm-Cell Therapeutics BCLI | 1 | P3 1 | 0 | 0 |
| Coya Therapeutics COYA | 1 | P3 1 | 0 | 1 |
| Gipfel Life Sciences GmbH | 1 | P3 1 | 0 | 0 |
| Ionis Pharmaceuticals, Inc. IONS | 1 | P3 1 | 0 | 0 |
| MediciNova MNOV | 1 | P3 1 | 0 | 1 |
| Prilenia | 1 | P3 1 | 0 | 0 |
| Rapa Therapeutics LLC | 1 | P3 1 | 0 | 0 |
| Shanghai Zhimeng Biopharma, Inc. | 1 | P3 1 | 0 | 0 |
| Spinogenix | 1 | P3 1 | 0 | 0 |
| Neuralink Corp | 7 | NA 7 | 1 | 0 |
| Eli Lilly and Company LLY | 4 | P1 4 | 1 | 0 |
| Cognixion | 3 | NA 3 | 1 | 0 |
| Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 2 | P1 1, P2 1 | 0 | 0 |
| RJK Biopharma Ltd | 2 | P1 1, EARLY_P1 1 | 0 | 1 |
| Synchron, Inc. | 2 | NA 2 | 0 | 1 |
| 1ST Biotherapeutics, Inc. | 1 | P1 1 | 0 | 0 |
| AC Immune SA ACIU | 1 | EARLY_P1 1 | 0 | 0 |
| Ambulanzpartner Soziotechnologie APST GmbH new entrant | 1 | NA 1 | 1 | 0 |
| Amylyx Pharmaceuticals Inc. AMLX | 1 | P1 1 | 0 | 1 |
| Ashvattha Therapeutics, Inc. | 1 | P2 1 | 0 | 0 |
| Biocells Medical | 1 | NA 1 | 0 | 0 |
| Brain Trust Bio | 1 | P1 1 | 0 | 0 |
| Cellenkos, Inc. | 1 | P1 1 | 0 | 1 |
New-entrant sponsors: Ambulanzpartner Soziotechnologie APST GmbH.
Recently stopped trials
- NCT05151471 Shionogi - terminated: Futility Analysis of parent study MT-1186-A02 was met. Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
- NCT06441682 argenx - terminated: The study was terminated following review of interim data indicating that continuation was unlikely to demonstrate a clinically meaningful t A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- NCT05683860 Wave Life Sciences USA, Inc. - terminated: Wave decided to stop the development of WVE-004 based on the available data findings. Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/
- NCT04569084 Shionogi - terminated: Futility was met. Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
- NCT06453668 ITB-Med LLC - terminated: The Sponsor has decided to terminate study early due to significant enrolment challenges since restarting the study in Dec 2025. The Sponsor A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-15 est. | P1/P2 | PLL TX AUSTRALIA PTY LTD | NCT06513546 A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients | Amyotrophic Lateral Sclerosis; ALS | not yet recruiting | 153 |
| 2027-01 est. | P1/P2 | Inflammasome Therapeutics | NCT07396818 Kamlanoflast In Amyotrophic Lateral Sclerosis | ALS (Amyotrophic Lateral Sclerosis); ALS; Neuro-Degenerative Disease; Neuro-Degenerative Diseases; M | not yet recruiting | 40 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P2 | Corcept Therapeutics CORT | NCT05407324 Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | active not recruiting | 279 |
| 2026-08-12 | P2 | argenx ARGX | NCT06441682 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | terminated | 60 |
| 2026-07 est. | P2 | Woolsey Pharmaceuticals | NCT05218668 Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) | Amyotrophic Lateral Sclerosis | active not recruiting | 40 |
| 2026-06-23 | P2 | Novartis Pharmaceuticals NVS | NCT06643481 A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | active not recruiting | 251 |
| 2026-06-17 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT04768972 FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sa | Amyotrophic Lateral Sclerosis | active not recruiting | 89 |
| 2026-06 est. | P2 | Clene Nanomedicine CLNN | NCT05299658 An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Ca | Amyotrophic Lateral Sclerosis | active not recruiting | 40 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "amyotrophic lateral sclerosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.